Cover Story
ClinicalReal-world Evidence
By Matthew Bin Han Ong
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
In Brief
Clinical Roundup
Drugs & Targets
NCI Trials
NCI Trials for October 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation - A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Group chairs propose funding strategy to jump-start correlative studies
- Karen Knudsen to leave ACS
- 2024 Lasker Awards honor discoveries in antitumor immunity, GLP-1-based drugs, and research, advocacy in HIV/AIDS